Live Breaking News & Updates on Raju Prasad

Stay updated with breaking news from Raju prasad. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

CRISPR Therapeutics (NASDAQ:CRSP) Trading Up 5.9%

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report)’s share price traded up 5.9% during mid-day trading on Wednesday . The company traded as high as $66.13 and last traded at $66.00. 856,731 shares were traded during trading, a decline of 48% from the average session volume of 1,654,993 shares. The stock had previously closed at […] ....

Robertw Baird , Raju Prasad , Samarth Kulkarni , Invesco Ltd , Therapeutics Company Profile , Capital Investment Advisors , Royal Bank , Norges Bank , Needham Company , Investment Management , Securities Exchange Commission , Wolfe Research , Get Free Report , Exchange Commission ,

CRISPR Therapeutics (NASDAQ:CRSP) Trading Up 5.9%

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report)’s share price traded up 5.9% during mid-day trading on Wednesday . The company traded as high as $66.13 and last traded at $66.00. 856,731 shares were traded during trading, a decline of 48% from the average session volume of 1,654,993 shares. The stock had previously closed at […] ....

Raju Prasad , Robertw Baird , Samarth Kulkarni , Therapeutics Company Profile , Norges Bank , Royal Bank , Needham Company , Capital Investment Advisors , Wolfe Research , Invesco Ltd , Securities Exchange Commission , Investment Management , Get Free Report , Exchange Commission ,

CRISPR Therapeutics (NASDAQ:CRSP) Price Target Cut to $84.00

CRISPR Therapeutics (NASDAQ:CRSP – Free Report) had its target price decreased by Citigroup from $89.00 to $84.00 in a report issued on Thursday morning, Benzinga reports. Citigroup currently has a buy rating on the stock. Several other research firms have also recently weighed in on CRSP. TheStreet upgraded shares of CRISPR Therapeutics from a d+ […] ....

Samarth Kulkarni , Raju Prasad , Avoro Capital Advisors , Therapeutics Company Profile , Investment Management , Securities Exchange Commission , Norges Bank , Capital International Investors , Free Report , Get Free Report , Exchange Commission , International Investors ,

CRISPR Therapeutics (NASDAQ:CRSP) Trading Down 0.2% on Analyst Downgrade

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) shares dropped 0.2% during mid-day trading on Friday after Citigroup lowered their price target on the stock from $89.00 to $84.00. Citigroup currently has a buy rating on the stock. CRISPR Therapeutics traded as low as $55.21 and last traded at $55.61. Approximately 176,023 shares traded hands […] ....

Raju Prasad , Samarth Kulkarni , Investment Management , Securities Exchange Commission , Wells Fargo Company , Cantor Fitzgerald , Vanguard Group Inc , Charles Schwab Investment Management Inc , Capital International Investors , Get Free Report , Wells Fargo , Exchange Commission , International Investors , Charles Schwab Investment Management , Schwab Investment Management , Stock Down ,

CRISPR Therapeutics (NASDAQ:CRSP) PT Lowered to $84.00 at Citigroup

CRISPR Therapeutics (NASDAQ:CRSP – Free Report) had its price objective lowered by Citigroup from $89.00 to $84.00 in a research report report published on Thursday, Benzinga reports. Citigroup currently has a buy rating on the stock. Several other analysts have also recently commented on CRSP. Robert W. Baird increased their target price on CRISPR Therapeutics […] ....

United States , Robertw Baird , Raju Prasad , Samarth Kulkarni , Securities Exchange Commission , Virtu Financial , Cetera Advisors , Free Report , Trading Down , Get Free Report , Exchange Commission , Investment Advisers , California State Teachers Retirement System , State Teachers Retirement System ,